SCHEMBL5481447

SCHEMBL5481447

O=C(Cc1cccc(C(F)(F)F)c1)Nc1cccc(-c2cn3ccnc3c(-n3ccnc3-c3ccc(Cl)cc3)n2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 17/20 0.66
KDR P35968 2/20 0.54
TEK Q02763 2/20 0.54
ABL1 P00519 1/20 0.54
EGFR P00533 1/20 0.54
PRKCB P05771 1/20 0.54
INSR P06213 1/20 0.54
LCK P06239 1/20 0.54
FYN P06241 1/20 0.54
LYN P07948 1/20 0.54
PDGFRB P09619 1/20 0.54
SRC P12931 1/20 0.54
PRKCA P17252 1/20 0.54
FLT1 P17948 1/20 0.54
FGFR4 P22455 1/20 0.54
EPHA2 P29317 1/20 0.54
AKT1 P31749 1/20 0.54
FLT4 P35916 1/20 0.54
FLT3 P36888 1/20 0.54
ZAP70 P43403 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482638 0.90 EPHB4 (0.56) EPHB4RET
SCHEMBL5479930 0.88 TP53 (0.56) EPHB4RET
SCHEMBL5477330 0.83 EPHB4 (0.64) EPHB4KDRTEKABL1EGFR
SCHEMBL5474112 0.82 EPHB4 (0.61) EPHB4
SCHEMBL5480930 0.79 BTK (0.59) EPHB4SYKBTK
SCHEMBL5482141 0.78 EPHB4 (0.62) EPHB4KDRTEKABL1EGFR
SCHEMBL5478322 0.77 EPHB4 (0.62) EPHB4KDRTEKABL1EGFR
SCHEMBL5486430 0.76 EPHB4 (0.57) EPHB4
SCHEMBL5481483 0.76 EPHB4 (0.57) EPHB4
SCHEMBL5485615 0.76 EPHB4 (0.85) EPHB4KDRTEKABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160885-B2 Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity CGI PHARMACEUTICALS, INC. (US) 2007-01-09 US claimed
US-20050054649-A1 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity XEROX CORPORATION 2005-03-10 US claimed
WO-2004072080-A1 CERTAIN 8-HETEROARYL-6-PHENYL-IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF HSP90 COMPLEX ACTIVITY CELLULAR GENOMICS, INC. (US) 2004-08-26 WO claimed
US-7160885-B2 Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity CGI PHARMACEUTICALS, INC. (US) 2007-01-09 US disclosed
US-7160885-B2 Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity CGI PHARMACEUTICALS, INC. (US) 2007-01-09 US disclosed
US-7160885-B2 Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity CGI PHARMACEUTICALS, INC. (US) 2007-01-09 US disclosed
US-20050054649-A1 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity XEROX CORPORATION 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054649-A1 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity HSP90AB1, HSP90AA1, HSPA9 EPHB4 4724/4885KDR 4073/4885TEK 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.